Navigation Links
Medisafe 1 Technologies Clarifies the PR Issued on September 1 for the Stock Dividend, as a Forward Split of 5-1 in the Form of a Stock Dividend
Date:9/3/2010

), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, will be issuing and completing a forward stock split of 5-1 in the form of a stock dividend on its common shares.

The Company anticipates the stock dividend will be payable on or about September 20 2010 to the shareholders of record on September 17 2010 and is subject to FINRA approval. When the stock dividend becomes effective, shareholders of each one restricted stock will receive an additional 4 shares of restricted stock and each shareholder of one unrestricted stock will receive an additional 4 shares of unrestricted stock. Medisafe 1 Technologies currently has 10,000,000 shares outstanding. The forward stock split in the form of the issuance of the dividend will increase the total shares outstanding to 50,000,000. Medisafe 1 expects the Board's decision will improve liquidity and trading volume in the Company's stock.

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ mater
'/>"/>

SOURCE Medisafe
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company
2. Medisafe 1 Technologies Finalises Contract to Develop Prototype of the Worlds First Ever Medicinal Syringe-Locking Device
3. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
4. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
5. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
6. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
7. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
8. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
9. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
10. Senesco Technologies Initiates Preclinical Studies for Cancer Target
11. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 2013 Oramed Pharmaceuticals Inc. (NASDAQCM: ... delivery systems, announced today that the United States Food ... New Drug application(IND) for ORMD-0801, its oral insulin capsule. ... FDA clearance to proceed," stated Nadav Kidron ... a major milestone for Oramed and we look forward ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... and MECHELEN, Belgium , May 17, ... (NYSE: ABBV ) announced today an extension ... disease.  Galapagos will fund and complete a Phase 2 ... rapid progression into Phase 3.  Upon successful completion of ... Galapagos $50 million.  The terms of the collaboration extension ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... and TARRYTOWN, N.Y., March 19, 2012   Siemens Healthcare Diagnostics ... for Clinical Pathology (ASCP) have awarded ... and graduate medical laboratory students for the 2011-2012 academic year. ... was established in 2003 to address the nation,s ...
... 2012 Avaxia Biologics, Inc., a privately-held biotech company ... therapeutics for the treatment of gastrointestinal diseases, is proud ... of funding from the National Institutes of Health for ... been awarded a Phase II Small Business Innovation Research ...
Cached Medicine Technology:Siemens and ASCP Award Over 100 Scholarships to Medical Laboratory Students in 2012 2Siemens and ASCP Award Over 100 Scholarships to Medical Laboratory Students in 2012 3Avaxia Biologics Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease 2
(Date:5/18/2013)... (May 19, 2013) The American Gastroenterological Association ... 2013 research scholars. This year,s honorees are outstanding ... hepatology or related areas, and with this award, ... "These young researchers are the future of our ... who are paving the way for promising research ...
(Date:5/18/2013)... News) -- Children who swallow high-powered magnets often need ... according to a new study. The researchers, from ... found that more than 79 percent of children who ... an endoscopic procedure, in which a tube containing a ... percent of these cases can be treated through observation ...
(Date:5/18/2013)... is associated with a reduced risk of primary ... Clinic research shows. The findings were being presented ... Orlando, Fla. , PSC is an inflammatory ... inflammation and subsequent fibrosis that can lead to ... cancer. , "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... May 18, 2013 Transvaginal mesh ... continue to move forward in a consolidated litigation underway ... LLP reports. According to a notice on the Court’s ... pelvic mesh litigation will be held on Wednesday, May ... been filed in the proceeding on behalf of women ...
(Date:5/18/2013)... 18, 2013 TheBeautyPlace.com answers important questions ... loss is not a result of stress, nutrient deficiency ... Fitness Magazine, 70% of men suffer from male patterned ... is renowned for hair transplant surgery, but additionally carries ... baldness known as Bosley Professional Strength. Their product line ...
Breaking Medicine News(10 mins):Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2Health News:Swallowing Magnets Can Be Fatal for Children 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 2Health News:TheBeautyPlace.com Features the Two New Best-Selling Hairloss Products: Bosley Professional Strength and Nioxin Systems 3
... pregnancy and childbirth are less likely to involve in ... with their newborns, interacting with // them etc. The ... the impact of mother’s depressive symptoms on her parenting ... behavior of more than 4,874 mothers from nearly 15 ...
... foods are under-diagnosed and under-treated, both in the community ... the American // Academy of Allergy, Asthma, and ... General Hospital in Boston and the Albany (N.Y.) Medical ... of Manitoba in Winnipeg, who is president of the ...
... Legionnaires disease thrives in poorly-maintained air-conditioning towers.,It is an air ... 10 days after initial exposure. // ,Symptoms include ... outbreak occurred in the north of Melbourne. So far ten ... 51-year-old man was tested positive to the airborne disease and ...
... A study conducted by Anna Johnson, a doctoral candidate ... that military veterans suffer from increased risk of heart ... found that combat veterans suffer 10-year risk of heart ... non-veterans. The results were presented at the American Heart ...
... York's Columbia University suggests that almost three-quarters of the ... two genes. AMD happens to be one of the ... "I am not aware of any other complex disorder ... said lead researcher Dr Rando Allikmets. "These findings are ...
... the dreaded bird flu had made an entry into neighboring Poland. ... died of bird flu. Since then the country has instituted a ... and Protection of Consumer Minister Horst Seehofer has said that cats ... homes, while it is compulsory to keep dogs on leashes. Entering ...
Cached Medicine News:Health News:Depressive Mothers Do Not Play Enough With Their Infants 2Health News:Number of Allergic Anaphylaxis Episodes Are Far More Than Those Recorded 2
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... liquid stable reagent offers the laboratory ... stability to help maximize laboratory productivity, ... result turnaround time. The patented technology ... a long shelf life that will ...
... Creatinine single liquid stable reagent offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... reagent provides a long shelf life ...
... The Infinity Amylase powder reagent ... the convenience of single liquid stability ... operator error and provide quick result ... the Infinity Amylase powder reagent provides ...
Medicine Products: